How has Solid Biosciences Inc.'s derivative liability, current changed year-over-year?

Solid Biosciences Inc.'s derivative liability, current decreased by 30.2% year-over-year, from $4.8M to $3.35M.

Solid Biosciences Inc. SLDB Derivative Liability, Current

Derivative Liability, Current at other companies

BiogenBIIB

——

BioMarin PharmaceuticalsBMRN

——

CytokineticsCYTK

——

Other financials

Income statement

See full

Revenue$2.0M-40.6%

Operating income-$57.3M-43.1%

Net income-$56.7M-44.4%

EPS (diluted)-$0.52+11.9%

Balance sheet

See full

Cash & equivalents$297.1M+41.1%

Total debt$20.7M-12.5%

Total equity$374.1M+27.1%

Total assets$422.9M+23.0%

Cash flow

See full

Operating cash flow-$47.2M-48.3%

CapEx$165.0K+31.0%

Free cash flow-$47.4M-48.2%

Valuation

See full

Market cap$872.26M+135%

Enterprise value$595.83M+223%

P/S107.8×-9.9×

Profitability

See full

Operating margin-1,315.2%-4,060pp

Net margin-1,062.3%-251,151pp

FCF margin-1,247.7%-9,569pp

Returns & leverage

See full

Return on equity-57.4%+2.2pp

Debt / equity0.1×0.0×

Current ratio13.1×+2.2×

Where this comes from

Reported directly by Solid Biosciences Inc. in its filing.

Tagged under the XBRL concept us-gaap:DerivativeLiabilitiesCurrent.

The official record: Solid Biosciences Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Solid Biosciences Inc.'s derivative liability, current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Solid Biosciences Inc.'s derivative liability, current?: Solid Biosciences Inc. (SLDB) reported derivative liability, current of $3.35M in Q1 2026.
How has Solid Biosciences Inc.'s derivative liability, current changed year-over-year?: Solid Biosciences Inc.'s derivative liability, current decreased by 30.2% year-over-year, from $4.8M to $3.35M.